Reaferon-Lipint capsules 500000IU, 10pcs

Composition

1 capsule-human recombinant Interferon alfa-2b 500,000 IU.

Auxiliary substances:

sodium chloride-8.01 mg,

sodium phosphoric acid di-substituted,

12-water (sodium hydrophosphate dodecahydrate) – 4.52 mg,

sodium dihydrogen phosphate dihydrate

monosubstituted 2-water-0.56 mg,

lactose monohydrate-91.34 mg,

colloidal anhydrous silicon dioxide-7.54 mg (not more than 5%).

Capsule shell composition (body and lid):

titanium dioxide (E 171) – 2%, gelatin – up to 100%.

Pharmacological action

The drug has an immunomodulatory and antiviral effect. Human recombinant Interferon alfa-2b, which is the Active ingredient in the preparation, is synthesized by bacterial cells of the Escherichia coli SG-20050/plF16 strain, in the genetic apparatus of which the human Interferon alfa-2b gene is embedded. It is a protein containing 165 amino acids and is identical in characteristics and properties to human leukocyte Interferon alfa-2b.

The antiviral effect of Interferon alfa-2b is manifested during the period of viral reproduction by active inclusion of cells in the metabolic processes. Interferon, interacting with specific receptors on the cell surface, initiates a number of intracellular changes, including the synthesis of specific cytokines and enzymes (2-5-adenylate synthetase and protein kinase), the action of which inhibits the formation of viral protein and viral ribonucleic acid in the cell.

The immunomodulatory effect of Interferon alfa-2b is manifested in an increase in the phagocytic activity of macrophages, an increase in the specific cytotoxic effect of lymphocytes on target cells, a change in the quantitative and qualitative composition of secreted cytokines, a change in the functional activity of immunocompetent cells, and a change in the production and secretion of intracellular proteins.

Indications

-treatment of influenza and other acute respiratory viral diseases in adults as part of complex therapy;

– prevention of influenza and other acute respiratory viral diseases in adults during epidemics and seasonal increase in morbidity.

Use during pregnancy and lactation

The drug is contraindicated for use during pregnancy and lactation.

Recommendations for use

The drug is taken orally,30 minutes before meals.

In the treatment of influenza and acute respiratory viral infections-500,000 IU (1 capsule) daily 2 times / day for 5 days.

For the prevention of influenza and acute respiratory viral infections – 500,000 IU (1 capsule) per day,2 times a week for a month.

If swallowing is difficult, the capsules are carefully opened, and the contents are taken with a small amount of water.

Contraindications

-children under 18 years of age;

– pregnancy;

– lactation period;

– lactase deficiency, lactose intolerance, glucose-galactose malabsorption syndrome—

– hypersensitivity to interferon or any other components of the drug.

With caution

-renal and / or hepatic insufficiency;

— severe myelosuppression.

Side effects

Possible allergic reactions, flu-like syndrome (chills, fever, fatigue, lethargy, headache, myalgia, arthralgia, loss of appetite).

Interaction

Interferon alpha is able to reduce the activity of P-450 cytochromes and, consequently, affect the metabolism of cimetidine, fepitoip, Curantyl, theophylline, diazepam, propranolol, and warfarin. some cytostatics. May increase neurotoxic effects. myelotoxic or cardiotoxic effects of drugs prescribed earlier or simultaneously with it. Co-use with CNS depressants, immunosuppressive drugs (including oral and parenteral forms of corticosteroids) should be avoided. Alcohol consumption during treatment is not recommended.

Overdose

No cases of overdose of the drug were observed. Possible increase in dose-dependent side effects. Treatment is symptomatic.

Special instructions

If you experience allergic reactions, you should consult a doctor.

Influence on the ability to drive vehicles and mechanisms

The use of the drug does not affect the ability to drive a vehicle or potentially dangerous mechanisms.

Storage conditions

The drug should be stored in a place protected from light and inaccessible to children at a temperature not exceeding 8°C.

Shelf

life is 3 years.

Active ingredient

Interferon alfa-2b

Conditions of release from pharmacies

By prescription

Dosage form

Capsules